40401 Search Results


absidia sp  (ATCC)
90
ATCC absidia sp
MICs of CMT-3 and AMB
Absidia Sp, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/absidia sp/product/ATCC
Average 90 stars, based on 1 article reviews
absidia sp - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
factor vii  (Santa Cruz Biotechnology)
86
Santa Cruz Biotechnology factor vii
Figure 6: SDS-PAGE and Western blot analysis of ERα (a), <t>factor</t> <t>VII</t> (b) and prothrombin (c) in rat liver tissue. The control for (a) is human ovar- ian tissue and the control for (b) and (c) is rat liver lysate.
Factor Vii, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/factor vii/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
factor vii - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier
fvii  (Santa Cruz Biotechnology)
86
Santa Cruz Biotechnology fvii
Figure 1. miR-135a Is Upregulated in HCC Tumor with High <t>FVII</t> Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected <t>with</t> <t>siRNAs</t> for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.
Fvii, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fvii/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
fvii - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier
dounce homogenizer 40401  (Active Motif)
90
Active Motif dounce homogenizer 40401
Figure 1. miR-135a Is Upregulated in HCC Tumor with High <t>FVII</t> Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected <t>with</t> <t>siRNAs</t> for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.
Dounce Homogenizer 40401, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dounce homogenizer 40401/product/Active Motif
Average 90 stars, based on 1 article reviews
dounce homogenizer 40401 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rbc lysis buffer 40401 es  (Yeasen Biotechnology)
90
Yeasen Biotechnology rbc lysis buffer 40401 es
Figure 1. miR-135a Is Upregulated in HCC Tumor with High <t>FVII</t> Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected <t>with</t> <t>siRNAs</t> for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.
Rbc Lysis Buffer 40401 Es, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rbc lysis buffer 40401 es/product/Yeasen Biotechnology
Average 90 stars, based on 1 article reviews
rbc lysis buffer 40401 es - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
40401-ba  (Walser GmbH)
90
Walser GmbH 40401-ba
Figure 1. miR-135a Is Upregulated in HCC Tumor with High <t>FVII</t> Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected <t>with</t> <t>siRNAs</t> for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.
40401 Ba, supplied by Walser GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/40401-ba/product/Walser GmbH
Average 90 stars, based on 1 article reviews
40401-ba - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
erythrocyte lysate #40401  (Yeasen Biotechnology)
90
Yeasen Biotechnology erythrocyte lysate #40401
Figure 1. miR-135a Is Upregulated in HCC Tumor with High <t>FVII</t> Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected <t>with</t> <t>siRNAs</t> for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.
Erythrocyte Lysate #40401, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erythrocyte lysate #40401/product/Yeasen Biotechnology
Average 90 stars, based on 1 article reviews
erythrocyte lysate #40401 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


MICs of CMT-3 and AMB

Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: MICs of CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques:

Inhibition of fungal viability by CMT-3 and AMB

Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: Inhibition of fungal viability by CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques: Inhibition, Control

Figure 6: SDS-PAGE and Western blot analysis of ERα (a), factor VII (b) and prothrombin (c) in rat liver tissue. The control for (a) is human ovar- ian tissue and the control for (b) and (c) is rat liver lysate.

Journal: Thrombosis and Haemostasis

Article Title: Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens

doi: 10.1160/th10-03-0201

Figure Lengend Snippet: Figure 6: SDS-PAGE and Western blot analysis of ERα (a), factor VII (b) and prothrombin (c) in rat liver tissue. The control for (a) is human ovar- ian tissue and the control for (b) and (c) is rat liver lysate.

Article Snippet: Factor VII was detected using primary FVII antibody (MC-19, Santa Cruz Biotechnology) at 1:200 with donkey anti-goat IgG (SC2020, Santa Cruz Biotechnology) at 1:2,000 dilution as the secondary antibody.

Techniques: SDS Page, Western Blot, Control

Figure 1. miR-135a Is Upregulated in HCC Tumor with High FVII Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected with siRNAs for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.

Journal: Molecular therapy. Nucleic acids

Article Title: Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma.

doi: 10.1016/j.omtn.2017.10.002

Figure Lengend Snippet: Figure 1. miR-135a Is Upregulated in HCC Tumor with High FVII Expression (A) Expression of miR-135a was compared between HCC tumors (T) and their contiguous normal regions (N). (B) HCC cell line Hep3B was treated with recombinant TF, FVIIa, or a PAR2 peptide agonist for 24 hr. The level of miR-135a was analyzed. (C) Hep3B cells were transfected with siRNAs for TF, FVII, or PAR2. Expression of miR-135a was examined after 24 hr. (D) Hep3B cells were transfected with mTOR siRNA. The level of miR-135a was evaluated after 24 hr. (E) (Left) Correlations between FVII and miR-135a levels in HCC and non-tumor counterparts were assessed. We grouped patients having higher FVII and miR-135a levels in the tumor than the normal region (+/+) with patients having lower FVII and decreased miR-135a (/). These cases were compared with those having negatively correlated levels of FVII and miR-135a (+/ and /+). (Right) Tumor/ normal ratio of miR-135a expression was compared using qRT-PCR in HCC tumors that had higher FVII levels than the adjacent normal region (FVII T > N) and those that had lower FVII than the normal region (FVII T < N). The data are pre- sented as mean ± SD. Statistically significant compared with controls at *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: Transient transfection of siRNAs against TF (sc-44984, Santa Cruz Biotechnology), FVII (sc-40401), PAR-2 (sc-36188), or miR-135a mimic (Thermo Fisher Scientific) was conducted in Hep3B cells in 6-well plates using GenMute siRNA transfection reagent (SignaGen Laboratories; Rockville, MD, USA) according to manufacturer’s recommendations, and a final concentration of 10, 20, or 40 nM of siRNA/miRNA was used accordingly.

Techniques: Expressing, Recombinant, Transfection, Quantitative RT-PCR

Figure 2. Atg14 Is a Direct Target of miR-135a (A) Schematic representation of predicted miR-135a bind- ing sequence at the 30 UTR of atg14 gene. (B) Hep3B cells were transfected with FVII siRNA for 24 hr. FVII protein (left) and Atg14 mRNA (right) levels were determined. (C) HCC cell lines Hep3B (left) and HepG2 (right) were transfected with a miR-135a mimic (20 nM, 40 nM), and the mRNA level of Atg14 was evaluated after 24 hr. (D) Hep3B cells were co- transfected with a miR-135a mimic and a reporter construct that contained the wild-type (WT) or mutated (MT) miR- 135a binding sequence. Post-transcriptional repression was determined by measuring the relative luciferase activity. (E) Correlations of HCC tumor/normal ratios of Atg14 and miR-135a expression were depicted. (F) Kaplan-Meier probability distributions showing disease-free survival ac- cording to miR-135a levels in HCC tumors compared with their paired non-tumor tissues. The data are presented as mean ± SD. Statistically significant compared with controls at *p < 0.05; ***p < 0.001.

Journal: Molecular therapy. Nucleic acids

Article Title: Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma.

doi: 10.1016/j.omtn.2017.10.002

Figure Lengend Snippet: Figure 2. Atg14 Is a Direct Target of miR-135a (A) Schematic representation of predicted miR-135a bind- ing sequence at the 30 UTR of atg14 gene. (B) Hep3B cells were transfected with FVII siRNA for 24 hr. FVII protein (left) and Atg14 mRNA (right) levels were determined. (C) HCC cell lines Hep3B (left) and HepG2 (right) were transfected with a miR-135a mimic (20 nM, 40 nM), and the mRNA level of Atg14 was evaluated after 24 hr. (D) Hep3B cells were co- transfected with a miR-135a mimic and a reporter construct that contained the wild-type (WT) or mutated (MT) miR- 135a binding sequence. Post-transcriptional repression was determined by measuring the relative luciferase activity. (E) Correlations of HCC tumor/normal ratios of Atg14 and miR-135a expression were depicted. (F) Kaplan-Meier probability distributions showing disease-free survival ac- cording to miR-135a levels in HCC tumors compared with their paired non-tumor tissues. The data are presented as mean ± SD. Statistically significant compared with controls at *p < 0.05; ***p < 0.001.

Article Snippet: Transient transfection of siRNAs against TF (sc-44984, Santa Cruz Biotechnology), FVII (sc-40401), PAR-2 (sc-36188), or miR-135a mimic (Thermo Fisher Scientific) was conducted in Hep3B cells in 6-well plates using GenMute siRNA transfection reagent (SignaGen Laboratories; Rockville, MD, USA) according to manufacturer’s recommendations, and a final concentration of 10, 20, or 40 nM of siRNA/miRNA was used accordingly.

Techniques: Sequencing, Transfection, Construct, Binding Assay, Luciferase, Activity Assay, Expressing